Extended Data Fig. 5: Antiviral CD4+ T cell are primed by cDC2 cells and differentiate independently of NK cells.
a, Schematic representation of the experimental procedure for the results described in panels b and c. 1 × 106 purified CD45.1+ Ag-specific (SMARTA) CD4+ T cells were injected into NKp46-DTR mice treated with PBS or DT as indicated. dLNs were collected 5 days after rVSV (blue) or rLCMV (red) infection. Percentages of NK cells (b), TFH (c, left) and TH1 (c, right) in dLNs were quantified by flow cytometry. Data are representative of 2 independent experiments. Mean+/- SEM is shown. n = 3. A one-way Anova with Bonferroni’s post-test was applied. * p value < 0.05; **** p value < 0.0001 (d) Schematics of the experimental setup for the results described in panel e. 1 × 106 purified CD45.1+ Ag-specific (SMARTA) CD4+ T cells were transferred to WT mice treated with anti-ICOS blocking antibody or with isotype control, as indicated, prior to rVSV (blue) or rLCMV (red) infection. dLNs were collected 3 days after infection. e, ICOSL expression (mean fluorescent intensity) within CD11c+ MHC-IIhigh CD8+ (cDC1) and CD11c+ MHC-IIhigh CD11b+ (cDC2) cell subsets in dLNs of the mice described in d. Data are representative of 2 independent experiments. Mean + /- SEM is shown. PBS conditions n = 2, all other conditions n = 3. A one-way Anova with Bonferroni’s post-test was applied. ** p value < 0.01; **** p value < 0.0001. f, 1 × 106 purified CD45.1+ Ag-specific (SMARTA) CD4+ T cells were transferred to WT and DT-treated XCR1-DTR mice prior to rVSV (blue, left) or rLCMV (red, right) infection. Quantification of TFH (left) and TH1 (right)—expressed as percentages of the total transferred cells—in dLNs 5 days after infection is shown. Mean ± SEM is shown. Data are representative of 2 independent experiments. n = 4-6.
